17Early
PostEra
Medicinal Chemistry powered by Machine Learning
UnfundedBoston, MA, USA· drug discovery and delivery· Ranked #10 of 30 in drug discovery and deliveryWebsite
Score breakdown
Momentum35
Capital1
Traction10
Capital & traction
- Total raised
- —
- Last round
- —
- Round size
- —
- Round date
- —
- Valuation
- —
- Disclosed revenue
- —
Embed this score on your site
Copy the embed code
<a href="https://steek.live/companies/869"><img src="https://api.steek.live/scoreboard/company/869/badge.svg" alt="Steek Score" width="248" height="64" /></a>Competitors in drug discovery and delivery
| Company | Raised | Score |
|---|---|---|
| WhiteLab Genomics Unleashing the potential of DNA and RNA based therapies using AI | $23M | 57 |
| Numerion Labs Artificial intelligence for drug discovery. | — | 17 |
| Verge Genomics We use human data and AI to develop better drugs faster. | — | 17 |
| Helix Nanotechnologies Next-generation mRNA platform to solve cancer, COVID and climate. | — | 17 |
| Macromoltek Computational antibody design | — | 17 |
| Synkrino Biotherapeutics Synkrino's AI, SATIS is a powerful, unbiased discovery system for… | — | 17 |
| Arpeggio Bio Arpeggio Bio develops drugs targeting transcription factors using AI… | — | 17 |
| Abalone Bio We create activating antibodies to treat diseases others can’t. | — | 17 |
| Trident Bioscience Accelerating protein engineering. | — | 17 |
| Menten AI Menten AI designs peptide and protein therapeutics using quantum… | — | 17 |
Signals behind the score
FAQs about PostEra
What is PostEra's Steek Score?
PostEra has a Steek Score of 17 (Early) — a transparent 0–100 momentum index built from funding, traction and attention signals.
What sector is PostEra in?
PostEra operates in drug discovery and delivery, where it ranks #10 of 30 by Steek Score.
Who are PostEra's competitors?
Top competitors include WhiteLab Genomics, Numerion Labs, Verge Genomics.
Where is PostEra located?
PostEra is based in Boston, MA, USA.
Steek Score is a transparent momentum index computed from tracked public signals. Not investment advice.